Form 4: Capricor Therapeutics Executive Sells Shares

Capricor Therapeutics, Inc. reports a Form 4 filing detailing stock transactions by EVP, General Counsel Karen Krasney.

Summary

• Karen Krasney, EVP and General Counsel of Capricor Therapeutics, Inc., reported transactions involving company stock on May 1, 2026.
• Krasney acquired 25,000 shares of common stock at an average price of $3.18 per share.
• Concurrently, Krasney sold 25,000 shares of common stock at a weighted average price of $31.7019 per share, with individual sale prices ranging from $30.88 to $33.19.
• These sales were executed under a pre-established Rule 10b5-1 trading plan.
• Following these transactions, Krasney beneficially owns 30,547 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the sale of shares by an executive can be a negative signal, the adherence to a Rule 10b5-1 plan mitigates concerns about insider trading and suggests a pre-determined strategy.

Positives

• Acquisition of 25,000 shares at a lower price point ($3.18), potentially indicating a belief in future stock appreciation or as part of an executive compensation plan.
• The sale of shares was conducted under a Rule 10b5-1 plan, which is designed to provide an affirmative defense against insider trading allegations by establishing a predetermined trading strategy.

Negatives

• A significant number of shares (25,000) were sold by a key executive, which could be interpreted negatively by the market, despite being part of a pre-planned strategy.
• The sale price ($31.7019 average) is substantially higher than the acquisition price ($3.18), indicating a significant profit for the executive, but also a large disposition of shares.

Risks

• The sale of a substantial number of shares by a high-ranking executive, even under a 10b5-1 plan, may create negative market sentiment or be perceived as a lack of confidence in near-term stock performance.
• The filing does not provide specific details on the reasons for the 10b5-1 plan's execution at this particular time, which could lead to speculation.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions described are historical events that occurred on May 1, 2026.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.88 to $33.19, inclusive.
• Shares vested 1/48th on the first day of each month commencing February 1, 2022.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for public companies, detailing stock transactions by insiders. The execution of a 10b5-1 plan is a common practice for executives to manage their stock holdings systematically and avoid potential insider trading concerns.

Stakeholder Impact

• Shareholders may interpret the sale of shares by a key executive, even under a 10b5-1 plan, with caution, potentially leading to short-term stock price fluctuations.
• Employees may view the executive's stock sale as a sign of confidence or a need for personal liquidity, depending on broader company performance and communication.

Next Steps

• Monitoring of Karen Krasney's beneficial ownership of Capricor Therapeutics, Inc. stock.
• Observation of market reaction to the reported stock transactions.

Key Dates

Recommendation

The filing details routine stock transactions by an executive under a pre-established 10b5-1 plan. While the sale of shares can be a negative signal, the plan's existence suggests a structured approach rather than a reaction to non-public information. Without further context on the company's performance or strategic outlook, a 'hold' recommendation is prudent, allowing for further observation.

Keywords

Form 4, Insider Trading, Stock Transaction, Capricor Therapeutics, Karen Krasney, Rule 10b5-1, Common Stock, Executive Compensation, Beneficial Ownership